[A25-117] Resmetirom (metabolic dysfunction-associated steatohepatitis) – Benefit assessment according to §35a Social Code Book V
Last updated 05.03.2026
Project no.:
A25-117
Commission:
Commission awarded on 15.09.2025 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Digestion, metabolism and hormones
Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3)
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
https://doi.org/10.60584/A25-117
| Project no. | Title | Status |
|---|---|---|
| A26-08 | Resmetirom (metabolic dysfunction-associated steatohepatitis) – Addendum to Project A25-117 | Commission completed |
Federal Joint Committee (G-BA)
05-03-2026 A G-BA decision was published.
G-BA documents on this decision